{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:15:18Z","timestamp":1788606918951,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Continued emergence of SARS-CoV-2 variants of concern that are capable of escaping vaccine-induced immunity highlights the urgency of developing new COVID-19 therapeutics. An essential mechanism for SARS-CoV-2 infection begins with the viral spike protein binding to the human ACE2. Consequently, inhibiting this interaction becomes a highly promising therapeutic strategy against COVID-19. Herein, we demonstrate that ACE2-expressing human lung spheroid cells (LSC)-derived exosomes (LSC-Exo) could function as a prophylactic agent to bind and neutralize SARS-CoV-2, protecting the host against SARS-CoV-2 infection. Inhalation of LSC-Exo facilitates its deposition and biodistribution throughout the whole lung in a female mouse model. We show that LSC-Exo blocks the interaction of SARS-CoV-2 with host cells in vitro and in vivo by neutralizing the virus. LSC-Exo treatment protects hamsters from SARS-CoV-2-induced disease and reduced viral loads. Furthermore, LSC-Exo intercepts the entry of multiple SARS-CoV-2 variant pseudoviruses in female mice and shows comparable or equal potency against the wild-type strain, demonstrating that LSC-Exo may act as a broad-spectrum protectant against existing and emerging virus variants.<\/jats:p>","DOI":"10.1038\/s41467-024-45628-x","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T20:02:14Z","timestamp":1710273734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-6726","authenticated-orcid":false,"given":"Zhenzhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8570-3439","authenticated-orcid":false,"given":"Shiqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6341-2251","authenticated-orcid":false,"given":"Kristen D.","family":"Popowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5786","authenticated-orcid":false,"given":"Dashuai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3847-6602","authenticated-orcid":false,"given":"Yilan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-6256","authenticated-orcid":false,"given":"Phuong-Uyen C.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-6893","authenticated-orcid":false,"given":"Ke","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"45628_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijsu.2020.02.034","volume":"76","author":"C Sohrabi","year":"2020","unstructured":"Sohrabi, C. et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int. J. Surg. 76, 71\u201376 (2020).","journal-title":"Int. J. Surg."},{"key":"45628_CR2","doi-asserted-by":"publisher","first-page":"eabe8065","DOI":"10.1126\/sciadv.abe8065","volume":"7","author":"PJ Klasse","year":"2021","unstructured":"Klasse, P. J., Nixon, D. F. & Moore, J. P. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Sci. Adv. 7, eabe8065 (2021).","journal-title":"Sci. Adv."},{"key":"45628_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","volume":"595","author":"U Sahin","year":"2021","unstructured":"Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595, 572\u2013577 (2021).","journal-title":"Nature"},{"key":"45628_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","volume":"599","author":"P Mlcochova","year":"2021","unstructured":"Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 599, 114\u2013119 (2021).","journal-title":"Nature"},{"key":"45628_CR5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41586-021-04266-9","volume":"602","author":"A Saito","year":"2022","unstructured":"Saito, A. et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 602, 300\u2013306 (2022).","journal-title":"Nature"},{"key":"45628_CR6","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1126\/science.abi7994","volume":"373","author":"M McCallum","year":"2021","unstructured":"McCallum, M. et al. SARS-CoV-2 immune evasion by the B.1.427\/B.1.429 variant of concern. Science 373, 648\u2013654 (2021).","journal-title":"Science"},{"key":"45628_CR7","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372\u20132383.e2379 (2021).","journal-title":"Cell"},{"key":"45628_CR8","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41591-021-01548-7","volume":"27","author":"KB Pouwels","year":"2021","unstructured":"Pouwels, K. B. et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med. 27, 2127\u20132135 (2021).","journal-title":"Nat. Med."},{"key":"45628_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41586-022-04479-6","volume":"603","author":"KPY Hui","year":"2022","unstructured":"Hui, K. P. Y. et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 603, 715\u2013720 (2022).","journal-title":"Nature"},{"key":"45628_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"45628_CR11","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41565-022-01174-5","volume":"17","author":"X Huang","year":"2022","unstructured":"Huang, X. et al. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat. Nanotechnol. 17, 1027\u20131037 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"45628_CR12","doi-asserted-by":"publisher","first-page":"e16109","DOI":"10.15252\/emmm.202216109","volume":"14","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2. EMBO Mol. Med. 14, e16109 (2022).","journal-title":"EMBO Mol. Med."},{"key":"45628_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25331-x","volume":"12","author":"Y Du","year":"2021","unstructured":"Du, Y. et al. A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. Nat. Commun. 12, 5000 (2021).","journal-title":"Nat. Commun."},{"key":"45628_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18058-8","volume":"11","author":"M Ejemel","year":"2020","unstructured":"Ejemel, M. et al. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nat. Commun. 11, 4198 (2020).","journal-title":"Nat. Commun."},{"key":"45628_CR15","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41586-021-03673-2","volume":"595","author":"Z Ku","year":"2021","unstructured":"Ku, Z. et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature 595, 718\u2013723 (2021).","journal-title":"Nature"},{"key":"45628_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41589-021-00965-6","volume":"18","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants. Nat. Chem. Biol. 18, 342\u2013351 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"45628_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41392-021-00653-w","volume":"6","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct. Target. Ther. 6, 233 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"45628_CR18","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181, 905\u2013913.e907 (2020).","journal-title":"Cell"},{"key":"45628_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16048-4","volume":"11","author":"C Lei","year":"2020","unstructured":"Lei, C. et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat. Commun. 11, 2070 (2020).","journal-title":"Nat. Commun."},{"key":"45628_CR20","doi-asserted-by":"publisher","first-page":"e2102957118","DOI":"10.1073\/pnas.2102957118","volume":"118","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Inhalable nanocatchers for SARS-CoV-2 inhibition. Proc. Natl Acad. Sci. USA 118, e2102957118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"45628_CR21","doi-asserted-by":"publisher","first-page":"6340","DOI":"10.1021\/acsnano.0c06836","volume":"15","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Membrane nanoparticles derived from ACE2-rich cells block SARS-CoV-2 infection. ACS Nano 15, 6340\u20136351 (2021).","journal-title":"ACS Nano"},{"key":"45628_CR22","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.matt.2021.04.005","volume":"4","author":"M Chen","year":"2021","unstructured":"Chen, M. et al. Nanotraps for the containment and clearance of SARS-CoV-2. Matter 4, 2059\u20132082 (2021).","journal-title":"Matter"},{"key":"45628_CR23","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41565-021-00923-2","volume":"16","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19. Nat. Nanotechnol. 16, 942\u2013951 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"45628_CR24","doi-asserted-by":"publisher","first-page":"2103471","DOI":"10.1002\/adma.202103471","volume":"33","author":"F Xie","year":"2021","unstructured":"Xie, F. et al. Engineering extracellular vesicles enriched with palmitoylated ACE2 as COVID-19 therapy. Adv. Mater. 33, 2103471 (2021).","journal-title":"Adv. Mater."},{"key":"45628_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27893-2","volume":"13","author":"L El-Shennawy","year":"2022","unstructured":"El-Shennawy, L. et al. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nat. Commun. 13, 405 (2022).","journal-title":"Nat. Commun."},{"key":"45628_CR26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11426-020-9943-9","volume":"64","author":"L Sun","year":"2021","unstructured":"Sun, L., Xiong, Z., Shen, F., Wang, Z. & Liu, Z. Biological membrane derived nanomedicines for cancer therapy. Sci. China Chem. 64, 719\u2013733 (2021).","journal-title":"Sci. China Chem."},{"key":"45628_CR27","doi-asserted-by":"publisher","first-page":"12194","DOI":"10.1021\/jacs.1c04933","volume":"143","author":"F Zhang","year":"2021","unstructured":"Zhang, F. et al. ACE2 receptor-modified algae-based microrobot for removal of SARS-CoV-2 in wastewater. J. Am. Chem. Soc. 143, 12194\u201312201 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"45628_CR28","doi-asserted-by":"publisher","first-page":"100017","DOI":"10.1016\/j.vesic.2022.100017","volume":"1","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Extracellular vesicles as novel therapeutic targets and diagnosis markers. Extracell. Vesicle 1, 100017 (2022).","journal-title":"Extracell. Vesicle"},{"key":"45628_CR29","doi-asserted-by":"publisher","first-page":"20200186","DOI":"10.1002\/VIW.20200186","volume":"2","author":"KD Popowski","year":"2021","unstructured":"Popowski, K. D., Dinh, P. U. C., George, A., Lutz, H. & Cheng, K. Exosome therapeutics for COVID\u201019 and respiratory viruses. View 2, 20200186 (2021).","journal-title":"View"},{"key":"45628_CR30","doi-asserted-by":"publisher","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science 367, eaau6977 (2020).","journal-title":"Science"},{"key":"45628_CR31","doi-asserted-by":"publisher","first-page":"100032","DOI":"10.1016\/j.vesic.2023.100032","volume":"3","author":"V Sharma","year":"2024","unstructured":"Sharma, V. & Mukhopadhyay, C. D. Exosome as drug delivery system: Current advancements. Extracell. Vesicle 3, 100032 (2024).","journal-title":"Extracell. Vesicle"},{"key":"45628_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14344-7","volume":"11","author":"PC Dinh","year":"2020","unstructured":"Dinh, P. C. et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat. Commun. 11, 1064 (2020).","journal-title":"Nat. Commun."},{"key":"45628_CR33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","volume":"182","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the gespiratory tract. Cell 182, 429\u2013446.e414 (2020).","journal-title":"Cell"},{"key":"45628_CR34","unstructured":"Ziegler, C. G. K. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181, 1016\u20131035.e1019 (2020)."},{"key":"45628_CR35","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.vesic.2022.100018","volume":"1","author":"R Li","year":"2022","unstructured":"Li, R. et al. Heparan sulfate proteoglycan-mediated internalization of extracellular vesicles ameliorates liver fibrosis by targeting hepatic stellate cells. Extracell. Vesicle 1, 100018 (2022).","journal-title":"Extracell. Vesicle"},{"key":"45628_CR36","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020).","journal-title":"Nature"},{"key":"45628_CR37","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.1016\/j.vesic.2022.100002","volume":"1","author":"KD Popowski","year":"2022","unstructured":"Popowski, K. D. et al. Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung. Extracell. Vesicle 1, 100002 (2022).","journal-title":"Extracell. Vesicle"},{"key":"45628_CR38","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1126\/science.abe2402","volume":"370","author":"A Baum","year":"2020","unstructured":"Baum, A. et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370, 1110\u20131115 (2020).","journal-title":"Science"},{"key":"45628_CR39","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","volume":"21","author":"ES Winkler","year":"2020","unstructured":"Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327\u20131335 (2020).","journal-title":"Nat. Immunol."},{"key":"45628_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.toxlet.2015.02.012","volume":"234","author":"J Jiang","year":"2015","unstructured":"Jiang, J. et al. Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol. Lett. 234, 139\u2013150 (2015).","journal-title":"Toxicol. Lett."},{"key":"45628_CR41","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s10930-020-09935-8","volume":"39","author":"S Suhail","year":"2020","unstructured":"Suhail, S. et al. Role of oxidative stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) infection: a review. Protein J. 39, 644\u2013656 (2020).","journal-title":"Protein J."},{"key":"45628_CR42","doi-asserted-by":"publisher","first-page":"108697","DOI":"10.1016\/j.intimp.2022.108697","volume":"108","author":"PR Romao","year":"2022","unstructured":"Romao, P. R. et al. Viral load is associated with mitochondrial dysfunction and altered monocyte phenotype in acute severe SARS-CoV-2 infection. Int. immunopharmacol. 108, 108697 (2022).","journal-title":"Int. immunopharmacol."},{"key":"45628_CR43","first-page":"287","volume":"54","author":"OM Ighodaro","year":"2019","unstructured":"Ighodaro, O. M. & Akinloye, O. A. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alex. J. Med. 54, 287\u2013293 (2019).","journal-title":"Alex. J. Med."},{"key":"45628_CR44","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1172\/JCI31807","volume":"117","author":"D Marinkovic","year":"2007","unstructured":"Marinkovic, D. et al. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J. Clin. Invest. 117, 2133\u20132144 (2007).","journal-title":"J. Clin. Invest."},{"key":"45628_CR45","doi-asserted-by":"publisher","first-page":"14940","DOI":"10.1074\/jbc.M117.797944","volume":"292","author":"EP Tan","year":"2017","unstructured":"Tan, E. P. et al. Sustained O-GlcNAcylation reprograms mitochondrial function to regulate energy metabolism. J. Biol. Chem. 292, 14940\u201314962 (2017).","journal-title":"J. Biol. Chem."},{"key":"45628_CR46","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3390\/vaccines9080914","volume":"9","author":"A Yaqinuddin","year":"2021","unstructured":"Yaqinuddin, A., Shafqat, A., Kashir, J. & Alkattan, K. Effect of SARS-CoV-2 mutations on the efficacy of antibody therapy and response to vaccines. Vaccines 9, 914 (2021).","journal-title":"Vaccines"},{"key":"45628_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18319-6","volume":"11","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat. Commun. 11, 4541 (2020).","journal-title":"Nat. Commun."},{"key":"45628_CR48","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41551-022-00902-5","volume":"6","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat. Biomed. Eng. 6, 791\u2013805 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"45628_CR49","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41586-022-04661-w","volume":"605","author":"T Shapira","year":"2022","unstructured":"Shapira, T. et al. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature 605, 340\u2013348 (2022).","journal-title":"Nature"},{"key":"45628_CR50","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1126\/science.abc0870","volume":"369","author":"KK Chan","year":"2020","unstructured":"Chan, K. K. et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science 369, 1261\u20131265 (2020).","journal-title":"Science"},{"key":"45628_CR51","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, eabf1555 (2021).","DOI":"10.1126\/scitranslmed.abf1555"},{"key":"45628_CR52","doi-asserted-by":"crossref","unstructured":"Ikemura, N. et al. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo. Sci. Transl. Med. 14, eabn7737 (2022).","DOI":"10.1126\/scitranslmed.abn7737"},{"key":"45628_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91809-9","volume":"11","author":"S Tanaka","year":"2021","unstructured":"Tanaka, S. et al. An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. Sci. Rep. 11, 12740 (2021).","journal-title":"Sci. Rep."},{"key":"45628_CR54","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","volume":"184","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384\u20132393.e2312 (2021).","journal-title":"Cell"},{"key":"45628_CR55","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.vesic.2023.100029","volume":"2","author":"K Cheng","year":"2023","unstructured":"Cheng, K. & Kalluri, R. Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics. Extracell. Vesicle 2, 100029 (2023).","journal-title":"Extracell. Vesicle"},{"key":"45628_CR56","doi-asserted-by":"publisher","first-page":"100023","DOI":"10.1016\/j.vesic.2023.100023","volume":"2","author":"E Tzng","year":"2023","unstructured":"Tzng, E., Bayardo, N. & Yang, P. C. Current challenges surrounding exosome treatments. Extracell. Vesicle 2, 100023 (2023).","journal-title":"Extracell. Vesicle"},{"key":"45628_CR57","doi-asserted-by":"publisher","first-page":"100016","DOI":"10.1016\/j.vesic.2022.100016","volume":"1","author":"SA Walker","year":"2022","unstructured":"Walker, S. A. et al. Sucrose-based cryoprotective storage of extracellular vesicles. Extracell. Vesicle 1, 100016 (2022).","journal-title":"Extracell. Vesicle"},{"key":"45628_CR58","doi-asserted-by":"publisher","first-page":"100033","DOI":"10.1016\/j.vesic.2023.100033","volume":"3","author":"MA Djeungoue Petga","year":"2024","unstructured":"Djeungoue Petga, M. A. et al. A simple scalable extracellular vesicle isolation method using polyethylenimine polymers for use in cellular delivery. Extracell. Vesicle 3, 100033 (2024).","journal-title":"Extracell. Vesicle"},{"key":"45628_CR59","doi-asserted-by":"publisher","first-page":"100031","DOI":"10.1016\/j.vesic.2023.100031","volume":"2","author":"C Han","year":"2023","unstructured":"Han, C. et al. CD63-snorkel tagging for isolation of exosomes. Extracell. Vesicle 2, 100031 (2023).","journal-title":"Extracell. Vesicle"},{"key":"45628_CR60","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2144\/000112729","volume":"44","author":"RH Hubner","year":"2008","unstructured":"Hubner, R. H. et al. Standardized quantification of pulmonary fibrosis in histological samples. BioTechniques 44, 507\u2013517 (2008).","journal-title":"BioTechniques"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45628-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T14:43:13Z","timestamp":1713883393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45628-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["45628"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-45628-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L. is an employee of Xsome Biotech Inc. K.C. is a co-founder and equity holder of Xsome. Xsome provided no funding to the study. No other authors declare competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2236"}}